Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early surfactant versus expectant management in late preterm and early term infants with respiratory distress
2019-003764-45Phase 3Unknown
- Sponsor
- University of Leicester
- Start
- May 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Poractant alfa in respiratory distress syndrome (RDS) (2 arms), sponsored by University of Leicester. Primary endpoint: Duration of neonatal hospital stay. Status: unknown.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on 2019-003764-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003764-45.